Technology Enhanced Depression Intervention (TEDI)

描述（由申请人提供）：大多数成年患者在初级保健机构接受抑郁症治疗。不幸的是，很少有人接受符合推荐指南的治疗。目前的项目，技术增强抑郁症干预初级保健（TEDI），建议使用技术作为时间密集型提供者接触的替代品，使这种稀缺的治疗资源可以更有效地应用。 我们建议开发一个系统，通过无线双向通信设备（寻呼机）来监控患者的用药依从性。 寻呼机使我们能够发送药物提醒和教育信息，并监测依从性和副作用。如果出现不合规或严重副作用，系统能够自动联系供应商。此外，补充行为治疗将通过万维网提供。这个互动式多媒体教程将通过评估和反馈，心理教育，结构化练习，家庭作业和家庭作业监控来教授认知行为疗法中的行为技能。 TEDI并不意味着取代人类干预和治疗。 相反，它是一种补充工具，旨在增强提供者的治疗，并在需要进一步人为干预或判断时通知他们。认识到技术的好处和局限性，我们设想将这项技术整合到治疗抑郁症的分步护理方法中。 拟议的商业应用： 一个低成本的工具，加强治疗抑郁症的初级保健设置将有许多潜在的客户。第三阶段的商业化可能涉及与已经在我们的目标市场活跃的公司合作，如疾病管理公司、大型保险公司或生产抗抑郁药物的制药公司。

DESCRIPTION (provided by applicant): Most adult patients are treated for depression in primary care settings. Unfortunately, few receive treatment that meets the recommended guidelines. The current project, Technology Enhanced Depression Intervention for primary care (TEDI), proposes the use of technology as a substitute for time-intensive provider contact so that this scarce treatment resource can be applied more effectively. We propose to develop a system to monitor patient medication compliance via wireless two-way communication devices (pagers). Pagers enable us to send medication reminders and educational messages, and monitor compliance and side effects. In the event of noncompliance or serious side effects, the system is able to automatically contact providers. In addition, supplementary behavioral treatment will be delivered via the World Wide Web. This interactive multimedia tutorial will teach behavioral skills derived from cognitive-behavioral therapy using assessment and feedback, psychoeducation, structured exercises, homework, and homework monitoring. TEDI is not meant to take the place of human intervention and treatment. Rather, it is a supplemental tool, designed to augment providers' treatment and notify them when further human intervention or judgment is required. Recognizing both the benefits and limitations of technology, we envision this technology being integrated into a step-care approach to the treatment of depression. PROPOSED COMMERCIAL APPLICATIONS: A low-cost tool that enhances the treatment of depression in the primary care setting would have many potential customers. Phase 3 commercialization will likely involve partnership with a company already active in our target markets such as disease management companies, large insurance carriers, or pharmaceutical companies that make anti-depressant medication.